Gene · 6554
Papers3,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,134
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting NTCP for liver disease treatment: A promising strategy. | J Pharm Anal | 2024 | 39310850 | PubTator, text mining | PubMed |
| IL-17A activates JAK/STAT signaling to affect drug metabolizing enzymes and transporters in HepaRG cells. | Mol Immunol | 2024 | 39305848 | PubTator, text mining | PubMed |
| The loss of hepatitis B virus receptor NTCP/SLC10A1 in human liver cancer cells is due to epigenetic silencing. | J Virol | 2024 | 39297647 | PubTator, text mining | PubMed |
| A tutorial on physiologically based pharmacokinetic approaches in lactation research. | CPT Pharmacometrics Syst Pharmacol | 2024 | 39283747 | PubTator, text mining | PubMed |
| The effect of pregnancy-related hormones on hepatic transporters: studies with premenopausal human hepatocytes. | Front Pharmacol | 2024 | 39170705 | PubTator, text mining | PubMed |
| Dysregulation of Human Hepatic Drug Transporters by Proinflammatory Cytokines. | J Pharmacol Exp Ther | 2024 | 39103232 | PubTator, text mining | PubMed |
| Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation. | Front Immunol | 2024 | 39091506 | PubTator, text mining | PubMed |
| Both middle and large envelope proteins can mediate neutralization of hepatitis B virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2 deletions. | J Virol | 2024 | 39078152 | PubTator, text mining | PubMed |
| Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury. | Int Immunopharmacol | 2024 | 39068755 | PubTator, text mining | PubMed |
| Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1-/-Ldlr-/- mice. | J Lipid Res | 2024 | 39009243 | PubTator, text mining | PubMed |
| Transporter Proteins as Therapeutic Drug Targets-With a Focus on SGLT2 Inhibitors. | Int J Mol Sci | 2024 | 39000033 | PubTator, text mining | PubMed |
| Immunomodulation and entry inhibition: selgantolimod's double punch against hepatitis B virus. | Gut | 2024 | 38969491 | PubTator, text mining | PubMed |
| Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library. | Antiviral Res | 2024 | 38964614 | PubTator, text mining | PubMed |
| Accurate Prediction of Protein Structural Flexibility by Deep Learning Integrating Intricate Atomic Structures and Cryo-EM Density Information. | Nat Commun | 2024 | 38956032 | PubTator, text mining | PubMed |
| Reactive Oxygen Species Induction by Hepatitis B Virus: Implications for Viral Replication in p53-Positive Human Hepatoma Cells. | Int J Mol Sci | 2024 | 38928309 | PubTator, text mining | PubMed |
| Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide. | J Hepatol | 2024 | 38901675 | PubTator, text mining | PubMed |
| SLC10A1 rs2296651 variant (S267F mutation) predicts biochemical traits, hepatitis B virus infection susceptibility and the risk of gallstone disease. | Mol Genet Genomics | 2024 | 38869622 | PubTator, text mining | PubMed |
| 3,3',5-Triiodothyroacetic Acid Transporters. | Thyroid | 2024 | 38836423 | PubTator, text mining | PubMed |
| [Study on mechanism of Chinese Yam polysaccharide synergizing nucleoside analogues against hepatitis B virus through p38 MAPK signaling pathway]. | Zhongguo Zhong Yao Za Zhi | 2024 | 38812178 | PubTator, text mining | PubMed |
| Oligomerization of drug transporters: Forms, functions, and mechanisms. | Acta Pharm Sin B | 2024 | 38799641 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6554/papers?page=9